吡柔比星载药微球联合洛铂在原发性肝癌介入栓塞治疗中的临床效果及不良反应分析★

Clinical efficacy and adverse reactions of pirarubicin-loaded microspheres combined with lobaplatin in interventional embolization therapy for primary liver cancer★

摘要:

目的 探究吡柔比星载药微球联合洛铂在原发性肝癌介入栓塞治疗中的临床效果及不良反应。方法 选取2020年6月—2022年6月河北北方学院附属第一医院收治的原发性肝癌中晚期患者92例，按随机数字表法分为对照组（n=46）和观察组（n=46）。所有患者均接受介入栓塞治疗，对照组患者给予洛铂灌注治疗，观察组患者在对照组的基础上联合吡柔比星载药微球进行治疗。比较两组患者的疗效，血管内皮生长因子（VEGF）、骨桥蛋白（OPN）、肿瘤坏死因子-α（TNF-α）、总胆红素（TBil）、丙氨酸转氨酶（ALT）水平和不良反应发生情况。结果 观察组患者总有效率（84.78%）显著高于对照组（65.22%）（P<0.05）；治疗后两组患者VEGF、OPN、TNF-α、TBil、ALT水平均显著低于治疗前，且观察组均显著低于对照组（P<0.05）；两组患者不良反应总发生率比较，差异无统计学意义（P>0.05）。结论 吡柔比星载药微球联合洛铂在原发性肝癌介入栓塞治疗中的效果较好，可提高疾病控制率，改善患者的肝功能。

Abstract:

Objective To investigate the clinical efficacy and adverse reactions of pirarubicin-loaded microspheres combined with lobaplatin in interventional embolization therapy for primary liver cancer.Methods A total of 92 patients with advanced primary liver cancer admitted to the First Affiliated Hospital of Hebei North University between June 2020 and June 2022 were selected in this study. Patients were assigned into the control group (n=46) and observation group (n=46) according to the random number table method. All patients were treated with interventional embolization. Patients in control group were treated by perfusion of lobaplatin, and those in observation group were treated with pirarubicin-loaded microspheres on the basis of the control group. The efficacy and the occurrence of adverse reactions were compared between the two groups, as well as the levels of vascular endothelial growth factor (VEGF), osteopontin (OPN), tumor necrosis factor-α (TNF-α), total bilirubin (TBil), and alanine transaminase (ALT).Results The total effective rate of the observation group (84.78%) was obviously higher than that of the control group (65.22%) (P<0.05). Compared with before treatment, the levels of VEGF, OPN, TNF-α, TBil, and ALT in the two groups were obviously reduced after treatment (P<0.05). After treatment, the levels of VEGF, OPN, TNF-α, TBil, and ALT in the observation group were obviously reduced when compared with the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion The combination of pirarubicin-loaded microspheres and lobaplatin showed a good effect in the interventional embolization therapy of primary liver cancer. It can improve the disease control rate and liver function of patients.